Targets › FLT4
24 programs from 22 companies in 354 trials: 264 Phase 2, 44 Phase 1, 37 Phase 3, 9 Phase 4; Oncology, Other, Respiratory; next expected readout Dec 2026.
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. (UniProt, P35916)
Open in Phaseline: the race on FLT4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group | Catequentinib Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 4 | Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma … | Dec 2026 |
| Takeda | Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 4 | Colorectal Cancer | Oct 2027 |
| Shanghai Junshi Bioscience Co., Ltd. | Lenvatinib mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Hepatocellular Carcinoma (HCC); Intrahepatic Cholangiocarcinoma | Dec 2026 |
| Ocular Therapeutix | Axitinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Neovascular Age-related Macular Degeneration; Non-Proliferative Diabetic Retinopathy; Neovascular Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD) … | Jan 2027 |
| Chia Tai Tianqing Pharmaceutical Group | AL2846 Capsule Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET | MET, KIT, FLT4, RET | Phase 3 | Thyroid Cancer | Jan 2027 |
| University Hospital, Bordeaux | PD-1/PD-L1 ICI + VEGFR-TKI combination PD-1/PD-L1 checkpoint inhibitor combined with VEGFR tyrosine kinase inhibitor | PDCD1, CD274, KDR, FLT1, FLT4 | Phase 3 | Metastatic Renal Cell Carcinoma | Jan 2027 |
| Merck & Co. (MSD) | Lenvatinib (MK-7902) Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Carcinoma, Renal Cell; Solid Tumors; Neoplasm Malignant; Esophageal Squamous Cell Carcinoma … | Feb 2027 |
| Advenchen Laboratories | Catequentinib (AL3818) Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor | KDR, FLT4, KIT, PDGFRB | Phase 3 | Alveolar Soft Part Sarcoma | Dec 2027 |
| AO GENERIUM | GNR-139 Aflibercept biosimilar; VEGF-A and PlGF antagonist; binds VEGFR1 and VEGFR2 | FLT1, KDR, FLT4 | Phase 3 | nAMD | May 2028 |
| Hutchmed | fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 3 | Advanced Endometrial Cancer; Advanced Renal Cell Carcinoma | Jan 2029 |
| Alliance for Clinical Trials in Oncology | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 3 | Clear Cell Renal Cell Carcinoma | Nov 2037 |
| Avalyn Pharma | Nintedanib (AP02) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF); Systemic Sclerosis; Telangiectasia, Hereditary Hemorrhagic; Non Small Cell Lung Cancer … | Dec 2026 |
| Henan Cancer Hospital | Lenvatinib Mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Effectiveness | Dec 2026 |
| Chipscreen Biosciences | Ibcasertib Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor | AURKB, FLT1, FLT4, KDR | Phase 2 | Pancreatic Ductal Adenocarcinoma | Feb 2027 |
| City of Hope Medical Center | Lenvatinib Mesylate Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma; Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 | Apr 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Anlotinib Hydrochloride multi-target tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR inhibitor) | KDR, PDGFRA, FLT4 | Phase 2 | Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer | Jun 2027 |
| Mannkind | Nintedanib (MNKD-201) Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor; Fibroblast growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 2 | Idiopathic Pulmonary Fibrosis | Dec 2027 |
| Criterium | Fruquintinib Vascular endothelial growth factor receptor inhibitor | FLT1, FLT4, KDR | Phase 2 | Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma … | Dec 2027 |
| Hutchmed | Surufatinib Fibroblast growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | FGFR1, FLT1, FLT4, KDR | Phase 2 | Metastatic Pancreatic Cancer; Neuroendocrine Tumors; Pancreatic Cancer, Adult; Intrahepatic Cholangiocarcinoma … | May 2028 |
| M.D. Anderson Cancer Center | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 2 | Renal Cell Carcinoma | Nov 2028 |
| University of Florida | Tivozanib Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Bile Duct Cancer | Dec 2026 |
| AstraZeneca | cediranib Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | KIT, PDGFRB, PDGFRA, FLT1, FLT4 | Phase 1 | Solid Tumors; Fallopian Tube Clear Cell Adenocarcinoma; Cervical Cancer; Mismatch Repair Proficient Colorectal Cancer … | Dec 2026 |
| Betta Pharmaceuticals | X-82 Platelet-derived growth factor receptor inhibitor; Vascular endothelial growth factor receptor inhibitor | PDGFRB, PDGFRA, FLT1, FLT4, KDR | Phase 1 | DDI (Drug-Drug Interaction); Hepatic Impairment (HI); Advanced Non-small Cell Lung Cancer (NSCLC); Vorolanib … | Jan 2027 |
| National Cancer Institute (NCI) | Tivozanib (AV-951) Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor | FLT1, FLT4, KDR, KIT, PDGFRB | Phase 1 | Cholangiocarcinoma | Dec 2028 |
Hepatocellular Carcinoma (13) Colorectal Cancer (12) Hepatocellular Carcinoma Non-resectable (7) Renal Cell Carcinoma (6) Intrahepatic Cholangiocarcinoma (6) Gastric Cancer (6) Breast Cancer (6) Metastatic Renal Cell Carcinoma (6) HCC (5) Cervical Cancer (5) Clear Cell Renal Cell Carcinoma (5) Hepatocellular Carcinoma (HCC) (5)
small molecule (13), mixed (10), antibody (1)
Chia Tai Tianqing Pharmaceutical Group (2) Hutchmed (2) Merck & Co. (MSD) (1) University Hospital, Bordeaux (1) Takeda (1) Tianjin Medical University Cancer Institute and Hospital (1) AO GENERIUM (1) Chipscreen Biosciences (1) National Cancer Institute (NCI) (1) Avalyn Pharma (1) Alliance for Clinical Trials in Oncology (1) Shanghai Junshi Bioscience Co., Ltd. (1) University of Florida (1) Mannkind (1) Advenchen Laboratories (1) Ocular Therapeutix (1) AstraZeneca (1) City of Hope Medical Center (1) Henan Cancer Hospital (1) Betta Pharmaceuticals (1)
KDR (22) FLT1 (20) PDGFRB (10) KIT (8) PDGFRA (5) PDCD1 (1) CD274 (1) AURKB (1) MET (1) RET (1) FGFR1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.